| Name | Title | Contact Details |
|---|
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
OPTI Medical Systems leverages advanced technologies to develop reliable, cost-effective point-of-care and laboratory diagnostic solutions.
Canada’s Global Life Sciences Venture / Partenaire d’affaires en sciences de la vie au Canada #lifesciences #biotech #sante
We provide deep scientific knowledge, global understanding and broad expertise to enhance market access and medical communications for improved health outcomes.
Industrial Pharmaceutical Resources is a Bartlett, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.